Translation

Notice: This document is an excerpt translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Summary of Consolidated Financial Results for the Year Ended July 31, 2023 (Based on Japanese GAAP)

September 11, 2023

Company name:	Pharma Foods International Co.,Ltd.			
Stock exchange listing:	Tokyo			
Stock code:	2929 URL https://www.pharmafood	ls.co.jp/		
Representative:	President	Mujo Kim		
Inquiries:	General Manager of Administration	Toshihiro Kawanaka TEL 075-394-8600		
inquiries.	Department	TOSHIIHO Kawaliaka TEL 075-594-8000		
Scheduled date of ordin	ary general meeting of shareholders:	October 25, 2023		
Scheduled date to file S	ecurities Report:	October 25, 2023		
Scheduled date to commence dividend payments:		October 26, 2023		
Preparation of suppleme	entary material on financial results:	Yes		
Holding of financial results meeting:		Yes (for institutional investors and analysts)		

(Amounts less than one million yen are rounded down)

1. Consolidated financial results for the year ended July 31, 2023 (from August 1, 2022 to July 31, 2023)

(1) Consolidated operating results Percentages indicate year-on-year changes								
	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Year ended July 31, 2023	68,572	13.9	3,610	234.1	3,540	179.9	3,081	-
Year ended July 31, 2022	60,185	28.7	1,080	(81.0)	1,264	(78.1)	(374)	-

	Earnings per share	I hilling earnings ner	Profit attributable to owners of parent/equity	Ordinary profit/total assets	Operating profit/net sales
	Yen	Yen	%	%	%
Year ended July 31, 2023	106.70	-	36.9	10.5	5.3
Year ended July 31, 2022	(12.89)	-	-	4.9	1.8

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
As of July 31, 2023	36,232	9,630	26.6	333.88
As of July 31, 2022	31,159	7,074	22.7	243.65

(3) Consolidated cash flows

	Cash flows from	Cash flows from	Cash flows from	Cash and cash equivalents
	operating activities	investing activities	financing activities	at end of period
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Year ended July 31, 2023	6,125	(1,013)	2,341	16,306
Year ended July 31, 2022	(6,065)	(2,539)	7,679	8,845

2. Cash dividends

		Annu	al dividends per	Total cash	Dividend payout	Ratio of dividends		
	1st quarter-end	2nd quarter-end	3rd quarter-end	Fiscal year-end	Total	dividends (Total)	ratio (Consolidated)	to net assets (Consolidated)
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Year ended July 31, 2022	-	10.00	-	10.00	20.00	580	-	7.5
Year ended July 31, 2023	-	10.00	-	12.00	22.00	634	20.6	7.6
Year ending July 31, 2024 (Forecast)	-	10.00	-	10.00	20.00		20.7	

3. Forecast of consolidated financial results for the year ending July 31, 2024 (from August 1, 2023 to July 31, 2024)

Percentages indicate year-on-yea									ar-on-year changes	
		Net sales		Operating profit		Ordinary profit		Profit attributa owners of pa		Earnings per share
		Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
	Full year	72,047	5.1	3,338	(7.5)	3,300	(6.8)	2,784	(9.6)	96.55

Yes

4. Notes

(1) Changes in significant subsidiaries during the year ended July 31, 2023

(changes in specified subsidiaries resulting in the change in scope of consolidation):

(2) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements
Changes in accounting policies due to revisions to accounting standards and other regulations:
Yes
Changes in accounting policies due to other reasons:
No
Changes in accounting estimates:
No
Restatement of prior period financial statements:
No

(3) Number of issued shares (common shares)

Total number of issued shares at the end of the period (including treasury shares)

As of July 31, 2023	29,079,000 shares	As of July 31, 2022	29,073,800 shares
Number of treasury shares at the end of the	period		
As of July 31, 2023	233,994 shares	As of July 31, 2022	52,483 shares
Average number of shares during the period	d		
Year ended July 31, 2023	28,876,505 shares	Year ended July 31, 2022	29,013,832 shares

Consolidated financial statements

Consolidated balance sheets

		(Millions of yen)		
	As of July 31, 2022	As of July 31, 2023		
Assets				
Current assets				
Cash and deposits	8,845	16,306		
Notes and accounts receivable - trade	6,702	4,058		
Electronically recorded monetary claims - operating	732	526		
Merchandise and finished goods	4,704	4,594		
Work in process	478	676		
Raw materials and supplies	884	783		
Other	1,175	588		
Allowance for doubtful accounts	(9)	(2		
Total current assets	23,513	27,530		
Non-current assets				
Property, plant and equipment				
Buildings and structures, net	2,549	2,449		
Machinery, equipment and vehicles, net	457	541		
Tools, furniture and fixtures, net	176	154		
Land	1,193	1,190		
Leased assets, net	31	21		
Construction in progress	50	47		
Total property, plant and equipment	4,458	4,404		
Intangible assets				
Goodwill	270	197		
Other	34	41		
Total intangible assets	305	238		
Investments and other assets				
Investment securities	1,572	2,514		
Deferred tax assets	47	395		
Other	1,262	1,149		
Allowance for doubtful accounts	(0)	(0		
Total investments and other assets	2,881	4,058		
Total non-current assets	7,645	8,701		
Total assets	31,159	36,232		

937
937
937
937
17,400
955
3,728
264
72
1,016
24,374
1,741
320
165
2,227
26,601
2,043
1,814
5,792
(343
9,306
324
324
9,630
36,232

Consolidated statements of income and consolidated statements of comprehensive income Consolidated statements of income

		(Millions of yen)
	Fiscal year ended	Fiscal year ended
	July 31, 2022	July 31, 2023
Net sales	60,185	68,572
Cost of sales	12,077	13,293
Gross profit	48,108	55,279
Selling, general and administrative expenses		
Research and development expenses	766	840
Advertising expenses	35,748	38,865
Commission expenses	3,412	4,090
Amortization of goodwill	51	72
Other	7,049	7,794
Total selling, general and administrative expenses	47,028	51,669
Operating profit	1,080	3,610
Mon-operating income		
Interest income	2	1
Dividend income	36	20
Foreign exchange gains	37	8
Subsidy income	94	54
Share of profit of entities accounted for using equity method	5	-
Outsourcing service income	16	10
Compensation income	_	25
Other	35	3:
Total non-operating income	228	16
Non-operating expenses		
Interest expenses	26	48
Loss on investments in investment partnerships		14
Loss on valuation of investment securities	_	50
Share of loss of entities accounted for using equity method	_	82
Commission expenses	14	30
Expenses related to product collection, etc.	_	
Other	2	
Total non-operating expenses	43	239
Ordinary profit	1,264	3,540
Extraordinary income	1,201	5,5 K
Gain on sale of non-current assets	77	
Gain on receipt of donated non-current assets	11	8
Gain on bargain purchase	82	(
Total extraordinary income	160	
	180	
Extraordinary losses		
Loss on valuation of investment securities	1	-
Loss on sale of non-current assets	_	(
Loss on retirement of non-current assets	0	-
Total extraordinary losses	1	(
Profit before income taxes	1,423	3,542
Income taxes - current	1,400	922
Income taxes - deferred	397	(46)
Total income taxes	1,797	462
Profit (loss)	(374)	3,080
Loss attributable to non-controlling interests	_	(1
Profit (loss) attributable to owners of parent	(374)	3,081

Consolidated statements of comprehensive income

onsonuated statements of comprehensive medine		
-		(Millions of yen)
	Fiscal year ended	Fiscal year ended
	July 31, 2022	July 31, 2023
Profit (loss)	(374)	3,080
Other comprehensive income		
Valuation difference on available-for-sale securities	37	278
Total other comprehensive income	37	278
Comprehensive income	(336)	3,358
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	(336)	3,359
Comprehensive income attributable to non-controlling		(0)
interests	—	(0)

Consolidated statements of changes in equity Fiscal year ended July 31, 2022

(Millions of yen)

	Shareholders' equity					
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity	
Balance at beginning of period	2,038	1,817	4,599	_	8,455	
Cumulative effects of changes in accounting policies			(37)		(37)	
Restated balance	2,038	1,817	4,561	-	8,417	
Changes during period						
Dividends of surplus			(871)		(871)	
Profit attributable to owners of parent			(374)		(374)	
Purchase of treasury shares				(299)	(299)	
Disposal of treasury shares		(15)		161	146	
Transfer from retained earnings to capital surplus		15	(15)		_	
Exercise of share acquisition rights	3	3			6	
Net changes in items other than shareholders' equity						
Total changes during period	3	3	(1,260)	(138)	(1,392)	
Balance at end of period	2,042	1,820	3,300	(138)	7,024	

	Accumulated other comprehensive income				
	Valuation difference on available- for-sale securities	Total accumulated other comprehensi ve income	Share acquisition rights	Non- controlling interests	Total net assets
Balance at beginning of period	8	8	1	_	8,465
Cumulative effects of changes in accounting policies					(37)
Restated balance	8	8	1	-	8,428
Changes during period					
Dividends of surplus					(871)
Profit attributable to owners of parent					(374)
Purchase of treasury shares					(299)
Disposal of treasury shares					146
Transfer from retained earnings to capital surplus					-
Exercise of share acquisition rights					6
Net changes in items other than shareholders' equity	37	37	(1)	2	39
Total changes during period	37	37	(1)	2	(1,353)
Balance at end of period	46	46	0	2	7,074

Fiscal year ended July 31, 2023

(Millions of yen)

	Shareholders' equity					
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity	
Balance at beginning of period	2,042	1,820	3,300	(138)	7,024	
Changes during period						
Dividends of surplus			(578)		(578)	
Profit attributable to owners of parent			3,081		3,081	
Purchase of treasury shares				(300)	(300)	
Disposal of treasury shares		(10)		94	84	
Transfer from retained earnings to capital surplus		10	(10)		_	
Additional purchase of shares of consolidated subsidiaries		(8)			(8)	
Exercise of share acquisition rights	1	1			2	
Net changes in items other than shareholders' equity						
Total changes during period	1	(6)	2,491	(205)	2,281	
Balance at end of period	2,043	1,814	5,792	(343)	9,306	

	Accumul	ated other			
	comprehensive income				
	Valuation	Total	Share	Non-	Total net
	difference on	accumulated	acquisition	controlling	assets
	available-	other	rights	interests	
	for-sale	comprehensi			
	securities	ve income			
Balance at beginning of period	46	46	0	2	7,074
Changes during period					
Dividends of surplus					(57
Profit attributable to owners of parent					3,08
Purchase of treasury shares					(30
Disposal of treasury shares					8
Transfer from retained earnings to capital surplus					-
Additional purchase of shares of consolidated subsidiaries					(
Exercise of share acquisition rights			(0)		
Net changes in items other than shareholders' equity	278	278		(2)	27
Total changes during period	278	278	(0)	(2)	2,55
Balance at end of period	324	324	_	_	9,63

Consolidated statements of cash flows

		(Millions of yen)
	Fiscal year ended	Fiscal year ended
	July 31, 2022	July 31, 2023
Cash flows from operating activities		
Profit before income taxes	1,423	3,542
Depreciation	469	474
Amortization of goodwill	51	72
Increase (decrease) in allowance for doubtful accounts	6	(7
Increase (decrease) in retirement benefit liability	(15)	(106
Increase (decrease) in provision for bonuses	(10)	1
Interest and dividend income	(38)	(28)
Subsidy income	(94)	(54)
Interest expenses	26	48
Loss (gain) on investments in investment partnerships	_	14
Foreign exchange losses (gains)	22	(5
Share of loss (profit) of entities accounted for using equity		
method	(5)	82
Gain on bargain purchase	(82)	_
Gain on sale of non-current assets	(77)	_
Loss on valuation of investment securities	1	50
Decrease (increase) in trade receivables	(1,020)	2,850
Decrease (increase) in inventories	(1,020) (2,247)	2,830
Decrease (increase) in inventories Decrease (increase) in consumption taxes refund receivable	(507)	642
Increase (decrease) in trade payables	(615)	(238
Increase (decrease) in accounts payable - other	584	(371
Increase (decrease) in accrued consumption taxes	(645)	191
Other, net	(350)	(18
Subtotal	(3,127)	7,153
Interest and dividends received	39	28
Interest paid	(29)	(48)
Subsidies received	80	59
Income taxes paid	(3,125)	(1,107)
Income taxes refund	97	39
Net cash provided by (used in) operating activities	(6,065)	6,125
Cash flows from investing activities		
Proceeds from withdrawal of time deposits	300	-
Purchase of property, plant and equipment	(467)	(386
Proceeds from sale of property, plant and equipment	306	3
Purchase of intangible assets	(5)	(19)
Purchase of investment securities	(1,021)	(700
Proceeds from redemption of investment securities	_	100
kari	(135)	=
Purchase of shares of subsidiaries resulting in change in scope		
of consolidation	(1,099)	-
Purchase of shares of subsidiaries and associates	(500)	
Other, net	(300) 81	(10)
Net cash provided by (used in) investing activities	(2,539)	(1,013)

		(Millions of yen)	
	Fiscal year ended	Fiscal year ended	
	July 31, 2022	July 31, 2023	
Cash flows from financing activities			
Net increase (decrease) in short-term borrowings	12,100	2,000	
Proceeds from long-term borrowings	_	2,000	
Repayments of long-term borrowings	(3,243)	(760)	
Proceeds from issuance of shares resulting from exercise of	5	2	
share acquisition rights	5	2	
Dividends paid	(871)	(578)	
Purchase of treasury shares	(299)	(300)	
Purchase of shares of subsidiaries not resulting in change in scope of consolidation	_	(10	
Other, net	(10)	(11)	
Net cash provided by (used in) financing activities	7,679	2,341	
– Effect of exchange rate change on cash and cash equivalents	(22)	5	
- Net increase (decrease) in cash and cash equivalents	(948)	7,460	
- Cash and cash equivalents at beginning of period	9,794	8,845	
	8,845	16,306	